Tradestie Institutional Equity Comparison Engine

RGNX vs RARE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RARE Overall Edge

RARE Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ultragenyx Pharmaceutical Inc. (RARE) driven by superior Valuation, Growth & Margin while RGNX counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus RARE at 11.2x Forward P/E and -59.9% operating margin (+8.1% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against RARE sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RARE
RGNX N/M vs RARE 11.2x Fwd P/E
Growth & Margin Winner RARE
Op Margin -120.4% vs -59.9% ยท YoY -69.2% vs +8.1%
Momentum & Technical Winner RGNX
1Y -36.0% vs -51.5% ยท 52W Pos 19% vs 12%
Options & Structure Winner RGNX
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (38th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
1M Return +7.58%
1Y Return -36.0%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
RARE NASDAQ
Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations
$15.96
-0.78% 1D
Market Cap $1.7B
1M Return +9.73%
1Y Return -51.5%
Forward P/E 11.2x
Unified AI Score
43.8 / 100 HOLD
Tech 36.0 Fund 53.0 Flow 68.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -36.0% RARE -51.5% Spread: +15.5 pp (RGNX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue RARE Revenue RGNX Op. Margin RARE Op. Margin Margin Edge
FY2018 $220M $50M 40.3% -721.2% RGNX
FY2019 $40M $100M -422.9% -409.0% RARE
FY2020 $150M $270M -77.1% -121.8% RGNX
FY2021 $470M $350M 34.0% -108.6% RGNX
FY2022 $110M $360M -233.2% -178.6% RARE
FY2023 $90M $430M -297.1% -131.1% RARE
FY2024 $80M $560M -280.0% -95.7% RARE
FY2025 $170M $670M -94.6% -79.5% RARE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (3) vs RARE (6)
Institutional Metric RGNX RARE Criterion Row Winner
Market Capitalization Scale $500.9M $1.7B Larger Scale RARE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M 11.2x Lower Multiple RARE
Revenue Growth (YoY) Growth -69.2% +8.1% Higher Growth RARE
Operating Margin (TTM) Profitability -120.4% -59.9% Higher Margin RARE
Net Profit Margin Profitability -113.9% -71.8% Higher Margin RARE
Return on Equity (ROE) Capital Efficiency -113.2% -608.5% Higher ROE RGNX
52-Week Range Position Momentum 19% ($5โ€“$16) 12% ($13โ€“$40) Stronger Trend RGNX
Beta / 30D Volatility Risk Regime 1.82ฮฒ ยท 76% Vol 1.40ฮฒ ยท 57% Vol Lower Realized Risk RARE
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs RARE Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RARE BREAKDOWN
93d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RARE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor RARE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.